Abstracts tagged "Quality of life and systemic lupus erythematosus (SLE)"

Abstract Number: 1676 • 2018 ACR/ARHP Annual Meeting
Health Related Quality of Life over Time in a Multi-Ethnic Cohort of Patients with Systemic Lupus Erythematosus and Correlation with Disease Activity and Organ Damage
Muhammad Mehmood Riaz^1,2, Liang SHEN³, Lay Kheng Teoh⁴, Rangi Kandane-Rathnayake⁵ and Aisha Lateef⁶, ¹Department of Medicine, National University Hospital, Singapore, Singapore, ²Department of Medicine, Aga Khan University, karachi, Pakistan, ³Biostatistics Unit, National University Health System, Singapore, Singapore, ⁴National University Hospital, Division of Rheumatology, University Medicine Cluster, Singapore, Singapore, ⁵School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ⁶Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic disease affecting the physical, social, and psychological well-being of patients. Health related quality of life (HRQoL) measures…
Abstract Number: 782 • 2018 ACR/ARHP Annual Meeting
Cognitive Impairment and Health-Related Quality of Life in a Lupus Cohort
Chrisanna Dobrowolski¹, Lisa Engel², Robin Green³, Lesley Ruttan⁴, Sabrina Lombardi⁴, Carmela Tartaglia⁵, Nicole Anderson², Kenneth Colosimo², Michelle Vitti², Dennisse Bonilla², Joan E. Wither⁶, Marvin J. Fritzler⁷, Dorcas Beaton⁸ and Zahi Touma², ¹University of Ottawa, Ottawa, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Brain and Therapeutics, Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁴Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁶Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁷Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are commonly affected by cognitive impairment (CI), with a meta-analysis finding a prevalence of 38%. Despite this high…
Abstract Number: 845 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Brief Group Psychoanalytic Psychotherapy in Patients with Systemic Lupus Erythematosus and Follow-up
Emilia Sato^1,2, Céu Conceiçao³, Ivone Meinão⁴ and Sergio Blay⁵, ¹Rheumatology Division. Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Div/Dept of Med, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ³Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁴Medicine, Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁵Psychiatry, Escola Paulista de Medicina, Universidade Federal de São Paulo, Sao Paulo, Brazil
Background/Purpose: There are few studies evaluating the effectiveness of psychotherapy in Systemic Lupus Erythematosus (SLE) patients. Objectives: To evaluate the effectiveness of brief group psychoanalytic…
Abstract Number: 1263 • 2017 ACR/ARHP Annual Meeting
Relevance and Utility of Patient Reported Outcomes Measurement Information System (PROMIS®) Instruments in SLE: A Qualitative Study
Shanthini Kasturi¹, Madeline Epsten², Adena Batterman³, Roberta Horton³, Juliette Kleinman³, Jillian Rose³, Jackie Szymonifka², Laura Robbins⁴ and Lisa A. Mandl¹, ¹Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Social Work Programs, Hospital for Special Surgery, New York, NY, ⁴Education & Academic Affairs, Hospital for Special Surgery, New York, NY
Background/Purpose: The measurement of patient reported outcomes is a priority for patient-centered high value care. This is particularly true in chronic systemic diseases such as…
Abstract Number: 1652 • 2017 ACR/ARHP Annual Meeting
Trajectories of Quality of Life in an Iception Cohort of Lupus Patients and Their Determinants
William Fung¹, Lily Lim², Jiandong Su³ and Zahi Touma⁴, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic disease with varying disease activity levels and morbidities over time; this can affect patients’ health related quality…
Abstract Number: 2615 • 2017 ACR/ARHP Annual Meeting
Non-Pharmacological Treatment on Fatigue, Depression, Disease Activity, and Quality of Life of Systemic Lupus Erythematosus: A Systematic Review
Monthida Fangtham¹, Jacob Louis Nash², Stephanie Hyon³, Raveendhara R. Bannuru⁴ and Chenchen Wang³, ¹Internal Medicine, University of New Mexico, Albuquerque, NM, ²Health Sciences Library and Informatics Center, University of New Mexico, Albuquerque, NM, ³Rheumatology, Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA, ⁴Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA
Background/Purpose: In recent years, non-pharmacological therapies have been deemed as potentially beneficial for patients with systemic lupus erythematosus (SLE). These include complementary and integrative approaches,…
Abstract Number: 2953 • 2017 ACR/ARHP Annual Meeting
Drivers of Satisfaction with Care in Lupus
Bhavika Sethi¹, Ailda Nika², Winston Sequeira³, Joel A. Block⁴, Sergio Toloza⁵, Ana Bertoli⁶, Ivana Blazevic⁷, Luis M. Vilá⁸, Ioana Moldovan⁹, Karina Torralba¹⁰, Davide Mazzoni¹¹, Elvira Cicognani¹¹, Sarfaraz Hasni¹², Berna Goker¹³, Seminur Haznedaroglu¹³, Josiane Bourré-Tessier¹⁴, Sandra V. Navarra¹⁵, Chi Chiu Mok¹⁶, Ann Clarke¹⁷, Michael Weisman¹⁸, Daniel J. Wallace¹⁹ and Meenakshi Jolly³, ¹University of Birmingham, Birmingham, United Kingdom, ²Rheumatology, Rush University Medical Center, Chicago, IL, ³Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Division of Rheumatology, Rush University Medical Center, Chicago, IL, ⁵Rheumatology, Hospital San Juan Batista, Catamarca, Argentina, Catamarca, Argentina, ⁶Instituto Reumatológico Strusberg, Córdoba, Argentina, ⁷Rheumatology, Universidad de Buenos Aires, Buenos Aires, Argentina, ⁸Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ⁹Rheumatology, Beaver Medical Group, Redlands, CA, ¹⁰Division of Rheumatology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA, ¹¹Department of Psychology, University of Bologna, Bologna, Italy, ¹²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹³Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, ¹⁴Rheumatology, University of Montreal, Montreal, QC, Canada, ¹⁵Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ¹⁶Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ¹⁷Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹⁸Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, ¹⁹Rheumatology, Cedars-Sinai Medical Center, Beverly Hills, CA
Background/Purpose: Although survival in SLE has improved, quality of life (QOL) remains poor. Physicians aim to reduce suffering and improve health outcomes, while maximizing efficiency…
Abstract Number: 1397 • 2016 ACR/ARHP Annual Meeting
Correlation and Responsiveness of Cutaneous Lupus Disease Area and Severity Index (CLASI) and Skindex-29 with Cutaneous Childhood Lupus Erythematosus (cSLE)
Ashwaq Aleed, CCHMC, cincinnati, OH; Pediatric, Qassim University, Qassim, Saudi Arabia
Correlation and Responsiveness of Cutaneous Lupus Disease Area and Severity Index (CLASI) and Skindex-29 with Cutaneous Childhood Lupus Erythematosus (cSLE) *Ashwaq AlEÕed, **Nora Al Mutairi ,…
Abstract Number: 1419 • 2016 ACR/ARHP Annual Meeting
Validation of the French Version of Lupus Patient Reported Outcome (LupusPRO), a Disease-Specific Patient Reported Outcome for Lupus Patients
Hervé Devilliers¹, Meenakshi Jolly², Maxime Samson³, Bernard Bonnotte⁴, Francois Maurier⁵, Pascal Sève⁶, Nadine Magy-Bertrand⁷, Denis Wahl⁸, Jean-Loup Pennaforte⁹, Thierry Martin¹⁰, Olivier Aumaître¹¹, Gilles Blaison¹², Philip Bielefeld¹³, Alexis Mathian¹⁴, Christine Binquet¹⁵ and Zahir Amoura¹⁴, ¹Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ²Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL, ³Dijon University Hospital, Dijon, France, ⁴Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁵Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁶Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ⁷CHU Jean-Minjoz, Service de médecine interne et immunologie clinique, Besançon, France, ⁸CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, France, Nancy, France, ⁹Internal Medicine, Internal medicine departement, CHU de Reims, Reims, France, ¹⁰Internal medicine and clinical immunology departement, Strasbourg University Hospital, Strasbourg, France, ¹¹Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, ¹²Internal medicine departement, Colmar Hospital, Colmar, France, ¹³Internal medicine and systemic disease unit, Dijon University Hospital, Dijon, France, ¹⁴Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ¹⁵INSERM, CIC 1432, Clinical Epidemiology Unit, Hôpital François Mitterrand, CHU de Dijon, Dijon, France
Background/Purpose: To assess validity and reliability of French LupusPRO in France. Methods: After cross-cultural adaptation and harmonization for France, the LupusPRO was administered along with…
Abstract Number: 1757 • 2016 ACR/ARHP Annual Meeting
Association of the Lupus Low Disease Activity State (LLDAS) with Health-Related Quality of Life
Vera Golder¹, Rangi Kandane-Rathnayake², Alberta Y. Hoi³, Molla Huq⁴, Worawit Louthrenoo⁵, Yuan An⁶, Zhanguo Li⁶, Shue Fen Luo⁷, Sargunan Sockalingam⁸, Chak Sing Lau⁹, Mo Yin Mok¹⁰, Aisha Lateef¹¹, Kate Franklyn³, Susan Morton¹², Sandra V. Navarra¹³, Leonid Zamora¹³, Yeong-Jian Wu⁷, Laniyati Hamijoyo¹⁴, Madelynn Chan¹⁵, Sean O'Neill¹⁶, Fiona Goldblatt¹⁷, Mandana Nikpour¹⁸, Eric F Morand³ and Asia Pacific Lupus Collaboration, ¹Southern Clinical School, Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ²Rheumatology, Monash University, Melbourne, Australia, ³Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ⁴Department of Medicine (Rheumatology), Melbourne University, Melbourne, Australia, ⁵Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁶Peking University People's Hospital, Beijing, China, ⁷Chang Gung University, Taoyuan County, Taiwan, ⁸University of Malaya, Kuala Lumpur, Malaysia, ⁹Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ¹⁰Queen Mary Hospital, Hong Kong, Hong Kong, ¹¹Medicine/Rheumatology, National University Health System, Singapore, Singapore, ¹²Monash Health, Melbourne, Australia, ¹³Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ¹⁴University of Padjadjaran, Bandung, Indonesia, ¹⁵Tan Tock Seng Hospital, Singapore, Singapore, ¹⁶University of New South Wales, Sydney, Australia, ¹⁷Royal Adelaide Hospital, Adelaide, Australia, ¹⁸Melbourne University, Melbourne, Australia
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with significant impairment of health-related quality of life (HR-QoL). Recently, meeting a definition of a Lupus Low Disease…
Abstract Number: 1763 • 2016 ACR/ARHP Annual Meeting
Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients with Systemic Lupus Erythematosus Following 7 Years of Treatment Exposure: Impact of Clinical Characteristics over Time
Vibeke Strand¹, Pam Berry², Xiwu Lin², Yumi Asukai³, James Fettiplace³ and Sulabha Ramachandran², ¹Stanford University School of Medicine, Palo Alto, CA, ²GSK, Philadelphia, PA, ³GSK, Uxbridge, Middlesex, United Kingdom
Background/Purpose: Despite improvements in medical care leading to improved survival, systemic lupus erythematosus (SLE) adversely affects patients’ health related quality of life (HRQoL). To explore…
Abstract Number: 1770 • 2016 ACR/ARHP Annual Meeting
The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the First 10 Years
Murray Urowitz¹, Dafna D Gladman², Nicole Anderson³, Jiandong Su⁴ and The Systemic Lupus International Collaborating Clinics (SLICC) Group , ¹Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the first 10 years Background/Purpose: The Medical Outcome Survey Short Form…
Abstract Number: 3235 • 2016 ACR/ARHP Annual Meeting
Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients with Systemic Lupus Erythematosus: Up to 7 Years of Treatment Exposure
Vibeke Strand¹, Pam Berry², Sulabha Ramachandran² and James Fettiplace³, ¹Stanford University School of Medicine, Palo Alto, CA, ²GSK, Philadelphia, PA, ³GSK, Uxbridge, Middlesex, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that causes long-term organ damage over time and impairment in health-related quality of life (HRQoL).…
Abstract Number: 3236 • 2016 ACR/ARHP Annual Meeting
Socio-Demographic and Clinical Factors Influencing Generic and Disease-Specific Quality of Life in Patients with Systemic Lupus Erythematosus: Results of a Prospective Multicenter Study
Hervé Devilliers¹, Jean-François Besancenot¹, Sylvain Audia², Bernard Bonnotte³, Francois Maurier⁴, Christiane Broussolle⁵, Nadine Magy-Bertrand⁶, Denis Wahl⁷, Jean-Loup Pennaforte⁸, Thierry Martin⁹, Olivier Aumaître¹⁰, Gilles Blaison¹¹, Geraldine Muller¹, Alexis Mathian¹², Christine Binquet¹³ and Zahir Amoura¹⁴, ¹Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ²Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France, ³Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁴Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁵Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ⁶CHU Jean-Minjoz, Service de médecine interne et immunologie clinique, Besançon, France, ⁷CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, ⁸Internal Medicine, Internal medicine departement, CHU de Reims, Reims, France, ⁹Internal medicine and clinical immunology departement, Strasbourg University Hospital, Strasbourg, France, ¹⁰CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ¹¹Internal medicine departement, Colmar Hospital, Colmar, France, ¹²Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ¹³INSERM, CIC 1432, Clinical Epidemiology Unit, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ¹⁴Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France
Background/Purpose: To describe demographic, socio-economic and lupus-related factors associated with health-related quality of life (HRQOL) in systemic lupus erythematosus (SLE), as measured by 2 generic…
Abstract Number: 3237 • 2016 ACR/ARHP Annual Meeting
Responsiveness and Its Magnitude in the 36-Item Short Form Health Survey and the Lupus Quality of Life Questionnaire in Patients with Active Disease
Stephanie Nantes¹, Jiandong Su² and Zahi Touma³, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: SF-36 and LupusQoL are Health-Related Quality-of-Life (HRQoL) questionnaires used in SLE. We determined: (1) concurrent construct validity of SF-36 and LupusQoL against disease activity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].